INTRODUCTION
Severe aplastic anemia (SAA), a rare multilineage bone marrow failure disorder, has an estimated annual incidence of two cases per million in the United States and Europe and four per million in parts of Asia [1, 2] . There is a biphasic distribution of onset, with peaks between 10 and 25 years of age and over 60 years of age [3] . The large majority of SAA diagnoses (over 80%) are termed 'acquired' SAA and thought to be caused by autoimmune destruction of hematopoietic stem cells; accordingly the disease can be treated and often cured by immunosuppressive therapy (IST) or marrow replacement through hematopoietic stem cell transplantation (HSCT) [3, 4] . HSCT from a human leukocyte antigen (HLA) matched sibling donor (MSD) has become the standard initial therapy for younger, newly diagnosed patients [3] [4] [5] , with long-term survival up to 95-100% in patients under 20 [6] [7] [8] .
IST with horse antithymocyte globulin (ATG) and cyclosporine is generally recommended for SAA patients who lack a MSD or are not good candidates for HSCT [3, 9, 10] . It takes an average of 3-4 months to see a hematologic response, with approximately 70-80% of patients having a full or partial response and achieving transfusion independence [3, 4] . However, up to 30% of patients eventually relapse [3, 11] and up to an additional 20% develop secondary clonal hematopoiesis [3, 10, 12, 13] . Patients with relapsed or refractory disease or clonal evolution may be considered for a matched unrelated donor (MUD) HSCT. Improvements in survival after MUD HSCT for SAA have been noted using reduced doses of total body irradiation (TBI) [14] , the substitution of some cyclophosphamide dosing with fludarabine [15, 16] , and the selection of donors who are fully HLA-matched to patients at the allele level. These approaches have helped lower graft failure, graft versus host disease (GVHD), and mortality, the major early barriers to MUD HSCT success in SAA [3] . Historically, umbilical cord blood HSCT in SAA has led to poor outcomes [17, 18] . Haploidentical HSCT in SAA has only more recently been attempted and, accordingly, there are limited published data regarding outcomes with this approach [19 & -21 & ]. Studies are underway to improve outcomes using alternative donors, as some patients will not have an available MSD or MUD and yet still require HSCT for cure. Additionally, in cases where first HSCT results in graft failure, it is important to note good success reported with second HSCT for salvage [22
PRESENTATION AND DIAGNOSTIC EVALUATION
Patients present with bruising, bleeding, pallor, infections, or fatigue, or a combination of these symptoms. The diagnosis of SAA includes at least 2 of 3 cytopenias defined by a neutrophil count less than 0.5 Â 10 9 /l, platelet count less than 20 Â 10 9 /l, or anemia with reticulocyte count less than 20 Â 10 9 /l. Very SAA occurs in patients who otherwise meet criteria but also have a neutrophil count less than 0.2 Â 10 9 /l [3, 25] . The differential diagnosis for SAA includes conditions such as reversible toxic or infectious exposure, malignancy, myelodysplasia, and genetic syndromes. Bone marrow examination, including both aspiration and biopsy, must be performed to look for diagnostic hypocellularity less than 25% (or 25-50% but with <30% residual hematopoietic cells) and rule out other conditions, such as malignancy with infiltrating cells or myelodysplasia with cytogenetics, and fluorescent in-situ hybridization (FISH) used, looking, at a minimum, at chromosomes 5, 7, and 8. Figure 1 outlines a diagnostic algorithm. Given the need for different treatment approaches, it is essential to rule out inherited bone marrow failure syndromes (IBMFS) with, at minimum, screening for Fanconi anemia and paroxysmal nocturnal hemoglobinuria. We also suggest screening for dyskeratosis congenita and Schwachman-Diamond syndrome. Although some IBMFS present without any phenotypic features, patients with the history and examination features listed in Table 1 should be considered for more extensive genetic evaluation with available focused screens (e.g., marrowSeq [26 && ]) or whole genome sequencing.
MATCHED SIBLING DONOR TRANSPLANTATION: INDICATIONS, RESULTS, STEM CELL SOURCE, AND CONDITIONING REGIMENS
MSD HSCT is the treatment of choice for patients diagnosed with SAA less than 40 years old. This standard of care has been adopted internationally and is recommended by different national treatment algorithms, including one adopted by the United Kingdom Paediatric Blood and Marrow Transplant Group (Fig. 2 ), leading to cure rates above 80% with higher rates (>90%) in pediatric series [8,27 & ; with 3-year overall survival (OS) of 91 and 86%, respectively, and event-free survival (EFS) of 87 and 83%, respectively. Another important risk factor for survival is stem cell source, with bone marrow favored over peripheral stem cells because of less GVHD [39] [40] [41] [42] .
KEY POINTS
Children presenting with a picture of SAA have a 10-20% chance of having an IBMFS, and careful assessment for signs or symptoms along with genetic screening for these disorders is of major importance.
Long-term survival after MSD and MUD HSCT exceed 90% in children; MSD HSCT is already considered standard of care for upfront therapy and MUD HSCT is being evaluated by some groups as primary therapy.
Late effects after HSCT for SAA are minimal with current strategies and compare favorably to upfront IST late effects, except for patients with chronic GVHD.
Ongoing studies will continue to challenge treatment algorithms and may lead to an even more expanded role for HSCT in SAA. [43] . This approach yielded consistently good results with survival up to 95% in younger patients. To reduce the dose of cyclophosphamide and its associated sideeffects, fludarabine was incorporated by some groups. Using fludarabine 120 mg/m 2 , cyclophosphamide 1200 mg/m 2 , and ATG [44] [45] [46] [47] [48] , patients over age 30 had an OS of 80 versus 60% (P ¼ 0.04) for those conditioned with conventional cyclophosphamide dosing [49] , with no primary engraftment failures and acceptable rates of acute and extensive chronic GVHD (10 and 13%, respectively). With these excellent results using chemotherapy-based regimens, especially in children, there is no current role for the use of TBI in MSD HSCT for pediatric SAA.
SDS

Serotherapy in preparative regimens improves outcomes
Very early data reported improved survival with the addition of ATG to cyclophosphamide in the preparative regimen [43] . A retrospective study from the European Society for Blood and Marrow Transplantation (EBMT) with 1886 MSD HSCT between 1999 and 2009 showed that the omission of ATG resulted in significantly lower survival [42] . Alemtuzumab was tested in a retrospective study with 50 pediatric and adult patients [50] showing a low incidence of chronic GVHD (4%), hinting at a significant role of alemtuzumab in GVHD prevention. A second retrospective study compared outcomes in 155 patients receiving ATG or alemtuzumab during conditioning with no difference between groups in engraftment, time to count recovery, full chimerism achievement and acute GVHD, but less chronic GVHD with alemtuzumab (11 vs. 26%,
]. Moreover, experience has shown that clonal evolution is more common after IST (up to 20% of cases) [52] . For these reasons, the role of MUD HSCT in the SAA population is being reevaluated.
MATCHED UNRELATED DONOR
The EBMT explored fludarabine-based conditioning in this setting without TBI [48] , whereas American and Japanese groups de-escalated the TBI dose to 200-300 cGy, and still achieved survival in the range of 60-65% [53, 54] . More recent results report even better outcomes. In 2015, Dufour and colleagues described 2 years OS for MUD recipients of 96%. More significantly, front-line MUD recipients had better EFS compared with IST recipients (92 vs. 40%, P ¼ 0.0001). In this study, 29 patients undergoing MUD HSCT received a fludarabine, alemtuzumab, and cyclophosphamide conditioning regimen. GVHD was low with 10% acute grade II-IV GVHD and 19% chronic GVHD (all cases limited). One patient experienced graft failure after 1-antigen mismatched transplant and there was one case of transplant-related mortality reported. Cumulative incidence of rejection at 2 years was 4%. Moreover, time from diagnosis to neutrophil recovery was superimposable in a recent comparison between MSD and MUD recipients, as well as compared to patients receiving IST, thus ruling out increased risks for severe infections while awaiting count recovery in ] presented the outcome of 508 HSCT from MUD in children and adults. Engraftment was 91%, acute GVHD grade at least III was 10%, and extensive chronic GVHD 11%. OS was 76% at 3 years, with children doing better than adults (hazard ratio for improved OS with age <20 was 1.45, 95% CI 1.01-2.10). These data still show increased GVHD with MUD compared with MSD HSCT, but no difference in OS. Stem cell source and age remain strong predictors of survival in the MUD setting, mirroring the experience of MSD HSCT. Other specific donor factors, such as telomere length, have been examined as prognostic factors. Their role is still not completely understood and requires further study [55 && ].
Matched unrelated donor hematopoietic stem cell transplantation conditioning regimen
A retrospective comparison between conditioning with or without low-dose TBI in a fludarabine-cyclophosphamide-ATG regimen was performed [56] . The two groups were different as most patients below age 14 did not receive TBI. OS, EFS, and rejection rates were similar, but there was a higher incidence of chronic GVHD with TBI (50 vs. 27%, P ¼ 0.06). The study suggested that young recipients with well-matched donors may not require low-dose TBI, potentially avoiding some long-term complications.
The EBMT SAA working party currently recommends fludarabine 120 mg/m 2 , cyclophosphamide 120 mg/kg, and ATG (or alemtuzumab based on some positive experiences with this substitution) [50,57 & 
,58
& ] as a preparative regimen for MUD HSCT. TBI 200 cGy can be added for patients above 14 years of age, in case of mismatched grafts, and may be considered for younger children if previously sensitized (transfusion refractory), to reduce the risk of graft rejection [59] . A BMT CTN study explored cyclophosphamide dose reduction in the context of fludarabine (120 mg/m 2 ), ATG (9 mg/kg), and 200 cGy TBI. Both 100 and 50 mg/kg cyclophosphamide doses led to good outcomes, but superior early survival was noted in the 50 mg/kg cohort (97.4% at 1 year) with 11.7% graft failure, 23.7% grades II-IV acute GVHD, and 22.5% chronic GVHD, suggesting this approach is also reasonable [60 & ]. Groups from Europe and America are studying the approach of MUD search at diagnosis in SAA patients lacking a MSD. If a suitable MUD is identified and available to donate bone marrow within 3-4 months from diagnosis, upfront MUD transplantation can be considered. If the choice is upfront IST, patients can be reassured that rescue rates with MUD HSCT after failed IST remain good with 74% EFS and OS at 2-year posttransplant.
MISMATCHED DONOR, CORD BLOOD, AND HAPLOIDENTICAL TRANSPLANTATION
International guidelines suggest SAA patients lacking a matched donor should be considered for alternative donor HSCT after multiple IST failures [59] . Experience with alternative donors is limited, however, studies in Europe and a BMT CTN trial in the United States are addressing this need with innovative approaches.
Umbilical cord blood hematopoietic stem cell transplantation
Small reports from Japanese and European groups show poor outcomes after umbilical cord blood with 2-year OS of 38-41% [17, 18] . Of note, these data suggest that myeloablative conditioning and lower total nucleated cell dose (<3.9 Â 10 7 /kg) are associated with reduced survival [17] . More recent reduced intensity approaches with fludarabine, low-dose cyclophosphamide, low-dose TBI, and ATG are more encouraging [18, 61] .
Haploidentical hematopoietic stem cell transplantation
Transplants from mismatched family donor had been reported in the past by different groups for refractory patients, generally with suboptimal outcomes [62] . ] and Gao (26 adults, reduced intensity conditioning with three agent GVHD prophylaxis: OS 82% at 2 years, GVHD 40%) [21 & ]. Limited data are available for a reduced intensity approach followed by T-replete haploidentical transplant and postinfusion cyclophosphamide GVHD prophylaxis. Overall 24 patients have been reported in two different series with OS approaching 70% and low-GVHD rates
Mismatched HSCT in SAA is improving, but with published outcomes lagging behind MUD and MSD survival, until studies demonstrate improvements, this approach should be restricted to refractory or multiply relapsed patients.
LATE EFFECTS
As previously discussed, up to 20% of patients treated with IST in childhood go on to develop secondary clonal hematopoiesis. A seminal study on the occurrence of malignant tumors after treatment of SAA with IST (n ¼ 860) or HSCT (n ¼ 748) All CI at 5 years BMD, bone mineral density; CI, cumulative incidence; GVHD, graft versus host disease; HSCT, hematopoietic stem cell transplantation; MSD, matched sibling donor; MUD, matched unrelated donor; RT, radiation therapy; SAA, severe aplastic anemia; SYN, syngeneic donor; TAI, thoraco-abdominal irradiation; TBI, total body irradiation; TLI, total lymphoid irradiation.
showed a 10-year cumulative incidence of 18.8% after IST compared with 3.1% after HSCT. After IST patients primarily develop hematologic malignancy, compared with solid tumors after HSCT. In the same study, the risk of solid tumors after HSCT was primarily driven by the use of radiation in the conditioning regimen [68] . Subsequent studies of malignancy after HSCT for SAA have shown rates up to 13%, but in each case driven by high rates of chronic GVHD and use of more than 400 cGy TBI [35, 69, 70] , which no longer applies to more recent reduced intensity regimens and their excellent outcomes. Many post-HCST malignancies are skin or thyroid in origin and easily treated [71] , whereas others are head and neck tumors in the field of radiation exposure in patients with chronic GVHD [35, 68] . The most contemporary studies of late effects after reduced intensity approaches to HSCT for SAA show much lower rates of secondary malignancy down to 2% or less [72, 73] . Aside from malignancy, additional side-effects of IST and HSCT need to be considered. Medications such as cyclosporine, used long-term for IST, can lead to renal dysfunction and persistent hypertension in up to 15% of patients, even after discontinuation. Overall very little is reported about other late effects after IST [74] . Late effects after reduced intensity HSCT for SAA show that these regimens are very well tolerated [71] [72] [73] . Table 2 shows most commonly reported late effects, including bone and endocrine issues, which are largely driven by steroid exposure in the treatment of chronic GVHD. Most patients, however, will go on to live healthy lives without impact on educational attainment or fertility, and only very minimal risk of late complications [71, 73] .
CONCLUSION
Improved HSCT strategies that have led to excellent survival, with low rates of GVHD and low rates of late effects, are helping to change the pediatric acquired SAA treatment algorithm. MSD HSCT is the standard of care upfront therapy. MUD HSCT is being evaluated for the same purpose. Alternative donor HSCT is being optimized to help capture patients who do not have a MSD or MUD. These evolving strategies may lead to an even more expanded role for HSCT in pediatric acquired SAA.
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